erlotinib hydrochloride has been researched along with Carcinoma, Anaplastic in 20 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (30.00) | 29.6817 |
| 2010's | 12 (60.00) | 24.3611 |
| 2020's | 2 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bhat, TA; Dheeraj, A; Nambiar, DK; Singh, RP; Singh, SP; Yim, DS | 1 |
| Abe, H; Domoto, Y; Hirakawa, Y; Honda, K; Miyashita, N; Nagase, T; Nakamura, M; Nangaku, M; Oda, Y; Oki, R | 1 |
| Kenzaka, T; Miyoshi, K; Nakaji, H | 1 |
| Atxner, J; Buchwald, D; Happe, A; Kröz, M; Matthes, H; Popp, S; Schad, F | 1 |
| Brattain, MG; Hauser, J; Hu, YP; Humphrey, LE; Li, W; Panasiewicz, M; Patil, SB | 1 |
| Altaha, R; Hogan, T; Williams, HJ | 1 |
| Choi, YJ; Kim, CH; Lee, JC; Lee, JK; Lee, SS; Na, II; Rho, JK; Ryoo, BY; Yang, SH; Yoo, YD | 1 |
| Greco, FA; Hainsworth, JD; Lane, CM; Murphy, PB; Naot, Y; Spigel, DR; Thompson, DS; Waterhouse, DM | 1 |
| Buchanan, SG; Dekoning, T; Eagleson, B; Essenburg, C; Kang, L; Kaufman, D; Staal, B; Su, Y; Vande Woude, GF; West, R; Zhang, YW | 1 |
| Alberts, DS; Baker, AF; Brewer, MA; Chambers, SK; Clouser, MC; Cohen, JL; Cui, H; Gordon, AN; Gordon, MS; Hatch, KD; Isaacs, JD; Janicek, MF; Nagle, RB; Roe, DJ; Wright, HM | 1 |
| Akar, U; Arun, BK; Hortobagyi, GN; LaFortune, TA; Nieves-Alicea, R; Tari, AM; Ueno, NT; Zhang, D | 1 |
| Azzariti, A; Colucci, G; Fratto, ME; Galluzzo, S; Maiello, E; Santini, D; Silvestris, N; Tommasi, S; Tonini, G; Vincenzi, B; Zoccoli, A | 1 |
| Dragnev, KH; Graham, RM; Memoli, VA; Petty, WJ; Swift, CB; Urbanic, JJ; Varela, VA; Voelzke, WR; Waller, LL | 1 |
| Buysschaert, I; Carmeliet, P; Christensen, IJ; Høyer-Hansen, G; Ladekarl, M; Lassen, U; Olesen, RK; Pappot, H; Pfeiffer, P; Rohrberg, KS; Skov, BG; Sørensen, M | 1 |
| Higashiyama, M; Kimura, T; Kiura, K; Kondoh, K; Kudoh, S; Minami, Y; Mitsudomi, T; Noguchi, M; Nokihara, H; Oda, M; Ohe, Y; Saito, H; Tachibana, K; Takeuchi, S; Tanaka, H; Uramoto, H; Yamada, T; Yano, S; Yasumoto, K; Yatabe, Y; Yokota, J; Yoshida, J | 1 |
| Azria, D; Bascoul-Mollevi, C; Campigna, E; Chardès, T; Coelho, M; Gaborit, N; Larbouret, C; Mach, JP; Pèlegrin, A; Robert, B | 1 |
| Bagnardi, V; Bertolini, F; Calleri, A; Cancello, G; Colleoni, M; Dellapasqua, S; Goldhirsch, A; Intra, M; Luini, A; Montagna, E; Pastrello, D; Perri, G; Rampinelli, C; Veronesi, P; Viale, G | 1 |
| Aldana, GQ; DE LA Cámara Gómez, J; Fernández, MJ; Fernández, MS; Folgar, SC; López, MR; López, R; Méndez, CM; Reinoso, CR; Vázquez, MR | 1 |
| Nguyen, D; Parr, AL; Steinberg, SM; Tan, AR; Yang, SX | 1 |
| Matuszczak, J; Rajebi, MR; Saif, MW; Shahrokni, A | 1 |
1 review(s) available for erlotinib hydrochloride and Carcinoma, Anaplastic
| Article | Year |
|---|---|
Targeting EGFR in bilio-pancreatic and liver carcinoma.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Benzenesulfonates; Biliary Tract Neoplasms; Carcinoma; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Liver Neoplasms; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Sorafenib | 2011 |
6 trial(s) available for erlotinib hydrochloride and Carcinoma, Anaplastic
| Article | Year |
|---|---|
Paclitaxel/carboplatin plus bevacizumab/erlotinib in the first-line treatment of patients with carcinoma of unknown primary site.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma; Carcinoma, Squamous Cell; Disease-Free Survival; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasms, Unknown Primary; Paclitaxel; Quinazolines; Survival Rate; Young Adult | 2009 |
Overexpression of tumor vascular endothelial growth factor A may portend an increased likelihood of progression in a phase II trial of bevacizumab and erlotinib in resistant ovarian cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Gene Expression Regulation, Neoplastic; Humans; Likelihood Functions; Ovarian Neoplasms; Platinum Compounds; Prognosis; Quinazolines; Treatment Outcome; Tumor Microenvironment; Up-Regulation; Vascular Endothelial Growth Factor A | 2010 |
Phase II trial of erlotinib and bevacizumab in patients with advanced upper gastrointestinal cancers.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Carcinoma; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gastrointestinal Neoplasms; Humans; Male; Middle Aged; Prospective Studies; Quinazolines; Survival Analysis; Treatment Outcome | 2012 |
Metronomic chemotherapy combined with bevacizumab and erlotinib in patients with metastatic HER2-negative breast cancer: clinical and biological activity.
Topics: Administration, Metronomic; Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Pharmacological; Breast Neoplasms; Capecitabine; Carcinoma; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Neoplastic Stem Cells; Quinazolines; Receptor, ErbB-2; Vascular Endothelial Growth Factor Receptor-2 | 2012 |
Phase II trial of erlotinib plus capecitabine as first-line treatment for metastatic pancreatic cancer (XELTA study).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatic Neoplasms; Quinazolines | 2013 |
Markers in the epidermal growth factor receptor pathway and skin toxicity during erlotinib treatment.
Topics: Acneiform Eruptions; Antineoplastic Agents; Biomarkers; Biopsy; Breast Neoplasms; Carcinoma; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Folliculitis; Gene Expression Profiling; Humans; Ki-67 Antigen; Mitogen-Activated Protein Kinases; Neoplasm Proteins; Phosphorylation; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Skin | 2008 |
13 other study(ies) available for erlotinib hydrochloride and Carcinoma, Anaplastic
| Article | Year |
|---|---|
Decursin inhibits EGFR-ERK1/2 signaling axis in advanced human prostate carcinoma cells.
Topics: Carcinoma; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Humans; Ligands; Male; MAP Kinase Signaling System; Phosphorylation; Prostate; Prostatic Neoplasms | 2023 |
Renal-limited ANCA-associated vasculitis during erlotinib treatment for lung carcinoma.
Topics: Aged; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Carcinoma; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Glomerulonephritis; Hematuria; Humans; Kidney; Lung; Lung Neoplasms; Male; Protein Kinase Inhibitors; Proteinuria | 2022 |
Iatrogenic pneumopericardium in the setting of carcinomatous pericarditis.
Topics: Adenocarcinoma of Lung; Aged; Carcinoma; Erlotinib Hydrochloride; Fatal Outcome; Female; Gefitinib; Humans; Iatrogenic Disease; Lung Neoplasms; Pericarditis; Pneumopericardium; Protein Kinase Inhibitors; Punctures; Radiography; Ventilators, Negative-Pressure | 2018 |
Intratumoral Mistletoe (Viscum album L) Therapy in Patients With Unresectable Pancreas Carcinoma: A Retrospective Analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Deoxycytidine; Endosonography; Erlotinib Hydrochloride; Female; Fever; Fluorouracil; Gemcitabine; Humans; Injections, Intralesional; Male; Middle Aged; Mitoxantrone; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Palliative Care; Pancreatic Neoplasms; Phytotherapy; Plant Extracts; Retrospective Studies; Survival Rate; Ultrasonography, Interventional; Viscum album | 2014 |
Heterogeneity of receptor function in colon carcinoma cells determined by cross-talk between type I insulin-like growth factor receptor and epidermal growth factor receptor.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cell Proliferation; Cell Survival; Colonic Neoplasms; Drug Evaluation, Preclinical; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Humans; Imidazoles; Mitogen-Activated Protein Kinases; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazines; Quinazolines; Receptor Cross-Talk; Receptor, IGF Type 1; Signal Transduction; Tumor Cells, Cultured | 2008 |
Oncocytic, focally anaplastic, thyroid cancer responding to erlotinib.
Topics: Aged; Carcinoma; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Point Mutation; Protein Kinase Inhibitors; Quinazolines; Thyroid Neoplasms; Tomography, X-Ray Computed | 2009 |
The role of MET activation in determining the sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma; Cell Line, Tumor; Cell Movement; Drug Resistance, Neoplasm; Enzyme Activation; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Amplification; Gene Expression Regulation, Neoplastic; Hepatocyte Growth Factor; Humans; Lung Neoplasms; Mutation; Neoplasm Invasiveness; Neoplasm Metastasis; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Quinazolines | 2009 |
MET kinase inhibitor SGX523 synergizes with epidermal growth factor receptor inhibitor erlotinib in a hepatocyte growth factor-dependent fashion to suppress carcinoma growth.
Topics: Animals; Carcinoma; Cell Cycle; Cell Growth Processes; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; Hepatocyte Growth Factor; Humans; Mice; Mice, Inbred C3H; Mice, SCID; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyridazines; Quinazolines; Receptors, Growth Factor; Triazoles; Xenograft Model Antitumor Assays | 2010 |
Silencing kinase-interacting stathmin gene enhances erlotinib sensitivity by inhibiting Ser¹⁰ p27 phosphorylation in epidermal growth factor receptor-expressing breast cancer.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Carcinoma; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p27; Drug Resistance, Neoplasm; Drug Synergism; Erlotinib Hydrochloride; Female; Gene Silencing; Genes, erbB-1; Humans; Mice; Mice, Nude; Phosphorylation; Protein Binding; Protein Kinases; Quinazolines; RNA, Small Interfering; Serine; Stathmin; Xenograft Model Antitumor Assays | 2010 |
High cyclin D3 expression confers erlotinib resistance in aerodigestive tract cancer.
Topics: Animals; Biomarkers, Pharmacological; Carcinoma; Cyclin D1; Cyclin D3; Cyclin E; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gastrointestinal Neoplasms; Gene Expression Profiling; Humans; Immunohistochemistry; Mice; NIH 3T3 Cells; Quinazolines | 2011 |
Hepatocyte growth factor expression in EGFR mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohort.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Amplification; Hepatocyte Growth Factor; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Quinazolines | 2011 |
In pancreatic carcinoma, dual EGFR/HER2 targeting with cetuximab/trastuzumab is more effective than treatment with trastuzumab/erlotinib or lapatinib alone: implication of receptors' down-regulation and dimers' disruption.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cell Line, Tumor; Cetuximab; Down-Regulation; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Inhibitory Concentration 50; Kaplan-Meier Estimate; Lapatinib; Mice; Mice, Nude; Mice, SCID; Pancreatic Neoplasms; Phosphorylation; Protein Multimerization; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Trastuzumab; Xenograft Model Antitumor Assays | 2012 |
Erlotinib-induced episcleritis in a patient with pancreatic cancer.
Topics: Carcinoma; Erlotinib Hydrochloride; Female; Humans; Middle Aged; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Scleritis | 2008 |